GNF5-amido-Me

Target: This ligand targets ABL1 myristoyl allosteric pocket in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for ABL1 myristoyl allosteric pocket. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings ABL1 myristoyl allosteric pocket into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC-Mediated Degradation Platform: GNF5-amido-Me can be used as a ligand module in PROTAC designs to recruit an E3 ligase and drive selective degradation of a chosen target protein. By tuning linker length and attachment chemistry, researchers can optimize ternary complex formation, ubiquitination efficiency, and degradation potency in cellular models.

• Structure-Activity Linker Optimization: Incorporate GNF5-amido-Me into PROTACs with systematically varied linkers to map how spatial orientation affects target engagement and productive ubiquitination. This approach supports structure–function studies, enabling identification of linker geometries that maximize target residence time, promote polyubiquitin chain assembly, and enhance proteasome-dependent turnover.

• Target Selectivity Profiling: Use GNF5-amido-Me–based PROTACs to evaluate degradation selectivity across related proteins and isoforms. Quantitative immunoblotting or proteomics can determine whether the ligand’s binding mode yields preferential degradation, helping distinguish true targeted degradation from off-target destabilization or non-specific stress responses.

• Mechanistic Studies of Ubiquitination: GNF5-amido-Me–derived PROTACs are suitable for dissecting degradation mechanisms, including E3 ligase recruitment, ubiquitin chain linkage patterns, and dependence on the proteasome. Experimental readouts such as ubiquitination assays, proteasome inhibition, and competition experiments clarify whether degradation is driven by efficient ternary complex formation.

GNF5-amido-Me is an ABL-targeting ligand derivative suitable for allosteric ABL degrader design. Its use in PROTAC construction requires careful selection of a linker vector that preserves ABL binding.

Structure: GNF5-amido-Me is an allosteric ABL ligand derivative containing a pyrimidine core, a trifluoromethoxy-substituted anilino group, and a methyl amide on a phenyl ring. The molecule combines lipophilic aryl domains with heteroaromatic nitrogens and amide hydrogen-bonding functionality.

Reactivity: For ABL-targeted PROTAC construction, this ligand should be modified only through a vector that preserves the allosteric ABL-binding pharmacophore. Because the structure contains a terminal methyl amide rather than a free acid or primary amine, direct coupling is limited; linker-ready analogs bearing a carboxyl, amine, amide-extension, or halide vector are preferred. Alkyl or PEG linkers may be paired with CRBN, VHL, or IAP ligands after confirming that the modified aryl-amide region retains ABL engagement.